81 related articles for article (PubMed ID: 21504707)
21. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer molecular subtypes as identified by immunohistochemistry in South African black women.
van Bogaert LJ
Breast J; 2013; 19(2):210-1. PubMed ID: 23294416
[No Abstract] [Full Text] [Related]
23. Molecular subgroups of small (pT1) breast carcinomas belonging exclusively to the ductal infiltrating variety.
Schneider J; Tejerina A; Perea C; Lucas R; Sánchez J
Cancer Genomics Proteomics; 2007; 4(6):399-402. PubMed ID: 18204202
[TBL] [Abstract][Full Text] [Related]
24. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
25. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
[TBL] [Abstract][Full Text] [Related]
26. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
27. Bilateral breast cancer: differential diagnosis using histological and biological parameters.
Gong SJ; Rha SY; Jeung HC; Roh JK; Yang WI; Chung HC
Jpn J Clin Oncol; 2007 Jul; 37(7):487-92. PubMed ID: 17673471
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics of triple-negative breast cancers.
Sasaki Y; Tsuda H
Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Li J; Liu X; Tong Z
Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
[TBL] [Abstract][Full Text] [Related]
32. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
33. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
34. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
35. [Triple-negative breast cancer--towards a new entity].
Miron L; Marinca A; Marinca M; Miron I
Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):51-8. PubMed ID: 18677903
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM
Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
[TBL] [Abstract][Full Text] [Related]
37. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
39. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients.
Ben Abdelkrim S; Trabelsi A; Missaoui N; Beizig N; Bdioui A; Anjorin A; Jomaa W; Mokni M
Pathol Res Pract; 2010 Nov; 206(11):772-5. PubMed ID: 20850937
[TBL] [Abstract][Full Text] [Related]
40. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
Crabb SJ; Cheang MC; Leung S; Immonen T; Nielsen TO; Huntsman DD; Bajdik CD; Chia SK
Clin Breast Cancer; 2008 Jun; 8(3):249-56. PubMed ID: 18650155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]